DetailsCategory: DNA RNA and CellsPublished on Friday, 04 December 2020 14:55Hits: 1020
GAITHERSBURG, MD, USA and SUZHOU BIOBAY, China I December 3, 2020 I Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, announced today that the company has received feedback from the U.S. Food and Drug Administration (FDA) and may now proceed with a planned Phase I clinical study of its leading drug candidate, STP705, for treatment of multiple types of liver cancer.
The FDA has provided valuable feedback on the company's proposed trial design for a "Phase 1 Multicenter, Open-Label, Dose Escalation Study and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced / Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy." The first patient is expected to be enrolled in the study in the first quarter of 2021. STP705 is a small interfering RNA (siRNA) therapeutic that utilizes a proprietary polypeptide nanoparticle (PNP)-enhanced delivery system to inhibit expression of TGF-1 and COX-2 in targeted tissue and cells. Preclinical animal models have demonstrated its effective anti-tumor activity for treatments of cholangiocarcinoma and hepatocellular carcinoma.
"Receiving the required feedback from the FDA now permits us to proceed with this Phase Istudy that represents an important step forward in demonstrating the broader clinical utility of our siRNA therapeutic candidates," said Patrick Y. Lu, PhD, Sirnaomics' Founder and CEO. "Liver cancer treatment remainsacritical unmet need globally and especially in Asian countries. Ourclinical strategy leveraging STP705's FDA Orphan Drug designation for the treatment of cholangiocarcinoma and hepatocellular carcinoma will potentially be highly beneficial to patients suffering these life threatening diseases in both the US and Asia. We are anticipating that this clinical study will contribute to the expanding clinical evidence supportingextensivetherapeutic potential of STP705 against various cancers."
"Liver cancer continues to be a devastating disease for patients with high mortality and high unmet medical need," stated Michael Molyneaux, MD, Sirnaomics' Chief Medical Officer. "This disease fits with Sirnaomics mission to bring lifesaving drugs to patients with severe debilitating medical illness. We hope to gain important insight into the potential safety and efficacy of STP705 in this Phase I trialand we expect to build on the data from this study to expand into other oncology indications."
About Liver Cancer
Liver cancer is a global health problem, with liver neoplasms representing the second-most frequent cause of cancer-related death. There are many different types of liver cancers including hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), liver angiosarcoma, hepatoblastoma and others. Additionally, liver is a highly metastasis-permissive organ. It is the most frequently afflicted organ by metastasis and liver metastases are much more common than primary hepatic tumors. The distinctive biology of the liver renders it intrinsically susceptible to metastases. The true prevalence of liver metastasis is unknown, but between 30% and 70% of patients dying of cancer have liver metastases and most patients with liver metastases will die of their disease.
STP705 and Liver Cancer
Over expressions of TGF-1 and COX-2 have been well-characterized as playing key regulatory roles in tumorigenesis. TGF- is produced by different liver cells and is demonstrated to induce tumor cell migration and survival. TGF- has been found to be overexpressed in metastatic HCC tissues. Overexpression of TGF- is generally accepted to be associated with metastasis and poor prognosis. COX-2 is reported to be highly expressed in cancer stem cells and promotes cell migration in HCC cell lines. Additionally, inhibition of COX-2 suppresses cell migration and induces apoptosis. As such TGF-1 and COX-2 are excellent therapeutic targets for treatment of liver cancer.
STP705 is composed of two siRNA oligonucleotides targeting TGF-1 and COX-2 mRNA respectively and formulated in nanoparticles with a proprietary Histidine-Lysine Co-Polymer (HKP) peptide. Each individual siRNA has demonstrated the ability to inhibit the expression of their target mRNA and combining the two siRNAs produces a synergistic effect that diminishes pro-fibrogenic, pro-inflammatory, and pro-tumorigenic factors. Sirnaomics has completed numerous pre-clinical studies that demonstrate that inhibition of TGF-1 and COX-2 is expected to result in the inhibition of tumor growth and provide an alternative approach for the treatment of various liver cancers. Molecular analyses of the effects of administering the combination demonstrated that the inhibition of these targets had effects on downstream gene products associated with numerous oncology targets. Additional immunohistochemistry and image analyses of the liver and tumor tissues demonstrated that animals treated with STP705 resulted in increased CD4+ and CD8+ T cell infiltration within the tumor microenvironment. Using STP705 for treatments of hepatocellular carcinoma and cholangiocarcinoma have been designated as Orphan Drug indications by U.S. FDA. STP705 has also been evaluated in a Phase IIa clinical trial for treatment of Non-melanoma skin cancer.
About Sirnaomics, Inc.
Sirnaomics, Inc., a leading privately held biopharmaceutical company for discovery and development of RNAi therapeutics, is a Delaware corporation headquartered in Gaithersburg, Maryland, USA, with subsidiaries in Suzhou and Guangzhou, China. The Company's mission is to develop novel therapeutics to alleviate human suffering and advance patient care in areas of high unmet medical need. The guiding principles of the company are: Innovation, Global Vision with a Patient Centered focus. Members of the senior management team have a combined experience in the biopharmaceutical industry, spanning clinical development, regulatory, financial and business management in both the USA and China. The company is supported by funding from institutional investors, corporate partnerships and government grants. Sirnaomics has developed a strong portfolio of intellectual property with an enriched product pipeline. The therapeutic areas of focus include oncology, anti-fibrotic, anti-viral and metabolic therapeutics. Learn more at http://www.sirnaomics.com.
SOURCE: Sirnaomics
Read this article:
Sirnaomics to Initiate Phase I Study of STP705 in Treatment of Primary and Metastatic Liver Cancer | DNA RNA and Cells | News Channels -...
- Pluristyx, panCELLa, and Implant Therapeutics Announce Definitive Merger Agreement - Business Wire - October 13th, 2022
- Johns Hopkins Scientists Have Developed a Nanobody That May Treat Parkinson's Disease - SciTechDaily - September 25th, 2022
- UMD students contribute to tech, health fields with summer research projects - The Diamondback - September 16th, 2022
- Pair of Hopkins teams receive $200K in technology grants - Maryland Daily Record - August 22nd, 2022
- RoosterBio and AGC Biologics team up to accelerate manufacture of cell and exosome therapies - BioPharma-Reporter.com - August 22nd, 2022
- Stem Cell Transplant Reverses Sickle Cell Disease in Adults - July 3rd, 2022
- LONGEVERON INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com - May 15th, 2022
- Top Ways To Rejuvenate Your Body And Improve Your Well-being - The Southern Maryland Chronicle - April 19th, 2022
- BioCardia Announces FDA Approval of Its IND for NK1R+ Mesenchymal Stem Cells for the Treatment of Patients Recovering from Acute Respiratory Distress... - April 19th, 2022
- Synthetic biology's past, present and future explored in timely new account - Winnipeg Free Press - April 6th, 2022
- US is Out of Step on Primate Research With Rest of World - NewsClick - October 5th, 2021
- A Look Inside A Termite's Gut Wins The 11th Annual Nikon Small World in Motion Competition - PRNewswire - August 18th, 2021
- What really happened in Wuhan? - The Sunday Guardian Live - The Sunday Guardian - June 6th, 2021
- UMD Researchers Perform Crucial Proof-of-Concept ... - December 20th, 2020
- US gets more help in raging battle against COVID-19 as FDA authorizes Moderna vaccine, the second allowed for emergency use - USA TODAY - December 20th, 2020
- Trump was one of the first 10 patients to get an experimental COVID-19 treatment under special use - Yahoo News - October 8th, 2020
- New toilet, a VR camera and science experiments are heading to t - KAKE - October 8th, 2020
- ShoreRivers awarded DNR grant for two restoration projects - MyEasternShoreMD - August 26th, 2020
- CRISPR cows could boost sustainable meat production, but regulations and wary consumers stand in the way - Genetic Literacy Project - August 26th, 2020
- Over $8M in 2020 Stem Cell Funding Awards Continue to Fuel Marylands Leading Cell Therapy Industry - BioBuzz - June 24th, 2020
- Researchers develop nanoengineered bioink to 3D print functional bone tissue - 3D Printing Industry - May 27th, 2020
- 'Virus Goes In, Virus Goes Out': Advocates Call For Release Of More Low-Level Prisoners To Stem Infection Rate - Kaiser Health News - May 22nd, 2020
- What Do New Neurons in the Brains of Adults Actually Do? - The Scientist - May 7th, 2020
- David C. Karli is Offering a New Ray of Hope Through Regenerative Medicine - RESPECT. - May 3rd, 2020
- Could Innate Immunology Save Us From the Coronavirus? - The New York Times - May 3rd, 2020
- Watch: Hogan orders closure of bars, restaurants, theaters and gyms, restricts gatherings - Maryland Daily Record - March 22nd, 2020
- Dr Borehams Crucible: The small cap biotechs trying to make a buck from coronavirus - Stockhead - March 9th, 2020
- The Aussie Biotech Companies Trying To Make A Buck From Coronavirus - D'Marge - March 9th, 2020
- Organoids, iPSCs, and advanced cell models: Advancing discovery from basic research to drug discovery - Science Magazine - March 4th, 2020
- Maryland Stem Cell Center Consortium & Core Facility ... - March 4th, 2020
- Serving those who serve - The Hub at Johns Hopkins - November 14th, 2019
- BioLineRx Presents Preclinical Data From Triple Combination of BL-8040, Anti PD-1 and Chemotherapy Demonstrating Significant Reduction in Pancreatic... - November 6th, 2019
- VetStem Biopharma Shares the Success Story of Ole who was Treated with VetStem Cell Therapy by Dr. Holly Mullen - PR Web - November 6th, 2019
- Contrasting of Applied Therapeutics Inc. (APLT) and Neuralstem Inc. (NASDAQ:CUR) - MS Wkly - November 6th, 2019
- Reviewing Synthetic Biologics Inc. (SYN)'s and Asterias Biotherapeutics Inc. (:)'s results - FinanceMercury - November 6th, 2019
- Comparing of Neuralstem Inc. (CUR) and Allakos Inc. (NASDAQ:ALLK) - MS Wkly - November 6th, 2019
- Head-To-Head Survey: Intrexon (NASDAQ:XON) versus US Stem Cell (NASDAQ:USRM) - Riverton Roll - September 25th, 2019
- Analyzing US Stem Cell (OTCMKTS:USRM) and Intrexon (OTCMKTS:XON) - TechNewsObserver - September 25th, 2019
- Reviewing Intrexon (NASDAQ:XON) & US Stem Cell (NASDAQ:USRM) - Mayfield Recorder - September 25th, 2019
- Artificially Engineering Intestine - Mirage News - September 25th, 2019
- Prothena Corporation plc (PRTA)'s Financial Results Comparing With Neuralstem Inc. (NASDAQ:CUR) - The EN Herald - September 25th, 2019
- cord_blood - Maryland - September 14th, 2019
- Stem Cells and Type 1 Diabetes: What the Future Has in ... - April 24th, 2019
- Stem Cell Therapy in Maryland | Stem Cell Professionals - April 5th, 2019
- Meristem - Wikipedia - January 17th, 2019
- Stem Cell Therapy in Annapolis Maryland | Stem Cell ... - October 25th, 2018
- Stem Cell Centers - Towson > Stem Cell Centers - October 6th, 2018
- STEM CELL THERAPY - Orthopedic and Wellness Maryland - September 5th, 2018
- Patient Resources | University of Maryland School of Medicine - September 5th, 2018
- Stem Cell Clinical Trial | University of Maryland Children ... - August 17th, 2018
- Baltimore, Maryland Stem Cell Transplants, Montgomery ... - August 17th, 2018
- Nervous System Stem Cells Can Replace Themselves, Give ... - July 3rd, 2018
- Excellence in Stem Cell Research | University of Maryland ... - June 24th, 2018
- Maryland Stem Cell Research Fund: 2014 Awardees - June 24th, 2018
- Catholic response to stem cells - Featured Today ... - October 14th, 2017
- Free stem cell Essays and Papers - 123HelpMe - October 12th, 2017
- How Stem Cell Therapy Can Help Repair and Regenerate Your Body - October 12th, 2017
- How Stem Cell Therapy Can Help Repair and ... - Mercola.com - September 4th, 2017
- Science and technology to get boost from CRS-12 mission - SpaceFlight Insider - August 12th, 2017
- Cannon Scholars visit National Institute of Standards and Technology - Dover Post - August 9th, 2017
- Lab-Grown, Virus-Free Stem Cells Repair Retinal Tissue in ... - August 9th, 2017
- Roanoke researchers pursue treatments for the type of deadly brain cancer affecting McCain - Roanoke Times - August 3rd, 2017
- The Maryland Stem Cell Research Fund (MSCRF) | Tedco - November 25th, 2016
- Center for Stem Cell Biology & Regenerative Medicine ... - November 14th, 2016
- Ginger | University of Maryland Medical Center - September 6th, 2016
- Johns Hopkins Team Creates Stem Cells From Schizophrenia ... - September 5th, 2016
- Human Induced Pluripotent Stem Cell Derived Neuronal Cells ... - August 18th, 2016
- Maryland Stem Cell Center Consortium and Core Facility ... - August 12th, 2016
- Human Stem Cells Institute - Wikipedia, the free encyclopedia - October 19th, 2015
- Patients' Own Genetically Altered Immune Cells Show ... - October 19th, 2015
- Maryland Stem Cell Research Fund: Funding Opportunities - July 2nd, 2015
- MRI based on a sugar molecule can tell cancerous from noncancerous cells - March 27th, 2015
- MD Stem Cells Release Optic Nerve Vision Loss Reversed ... - March 22nd, 2015
- TiGenix: TiGenix reports its full year 2014 results - March 18th, 2015
- Gene regulatory path revealed as target for therapy of aggressive pediatric brain cancer - March 10th, 2015
- American Spine offers experimental fix for pain -- Gazette.Net - January 28th, 2015
- American Spine offers experimental fix for pain - January 28th, 2015
- Toughest Breast Cancer May Have Met Its Match - December 9th, 2014
- Bid on Stem Cells and Alcohol-induced Tissue Injuries (R21 ... - November 12th, 2014
- Head, National Institutes of Health Stem Cell Technology ... - November 11th, 2014